Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease.

ABSTRACT:

Background

Clinical trials have recently incorporated plasma glial fibrillary acidic protein (GFAP) as an exploratory endpoint. To include plasma GFAP as a secondary endpoint, it is essential to characterize its longitudinal progression in target populations.

Objective

To evaluate the potential use of plasma GFAP changes as a secondary endpoint in Alzheimer's disease trials.

Methods

We longitudinally evaluated plasma GFAP in individuals with amyloid-beta (Aβ)-PET scans at baseline in three well-characterized cohorts. Cox proportional hazards regression tested the association between changes in plasma GFAP and cognitive function. Analysis of the 95 % confidence interval of annualized change in plasma GFAP provided statistical inference for a significant longitudinal ch

SUBMITTER: Abbas S 

PROVIDER: S-EPMC12321629 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature